The advice given by the PRA Company will be aligned to an organization’s current and projected future investments in PET. This will be within the context of its culture for clinical research, commitment to supporting drug development, ambitions to obtain research funding, undertake commissioned studies and to have a presence nationally and internationally.
The PRA Company offers a new way in which advice is provided to help organizations develop their portfolio of clinical research applications, formulate scientific and practical strategies along with internal and external recruitment and networking.
The advice will be derived through listening to and working with the organization to review, explore and facilitate its ambitions for PET and help develop the vision and road map for realizing these ambitions.
The advice will be based upon experience, access to additional foremost expertise, insight into and vision and enthusiasm for the future developments of PET both in technology and applications along with insight into national and international collaborations.